Medtronic Wins FDA Clearance For LigaSure RAS Maryland Instrument On Hugo RAS System

Medtronic (MDT) reported Q1 growth of 7% (excluding an extra week), driven by innovations in cardiac ablation, renal denervation, robotics, and pelvic health. Cardiac ablation revenue surpassed $2B, while pelvic health revenue grew 15%. The company is investing in robotics, structural heart, and neuroscience, and plans to focus on tuck-in acquisitions. Medtronic expects to discuss its growth outlook further at an upcoming Investor Day.

Medtronic received FDA clearance for its LigaSure RAS Maryland device, compatible with the Hugo robotic-assisted surgery system. The device is designed for vessel sealing in robotic-assisted procedures. Medtronic aims to expand Hugo's use to more soft-tissue surgeries. The device is already available in Europe. Medtronic is working to broaden Hugo's applications in the US, where it is currently approved for urologic procedures.

Medtronic (MDT) received FDA clearance for its LigaSure™ RAS Maryland instrument for use with the Hugo™ RAS robotic-assisted surgery system in the U.S. The device, already used in over 45 million procedures globally, expands the Hugo system's capabilities. Medtronic aims to broaden the system's applications in the U.S. and continues its international expansion.

Medtronic (MDT) launched an exchange offer to spin off its MiniMed diabetes business, focusing on cardiovascular, neuroscience, and surgical devices. The company also partnered with Sonus Microsystems to deploy AI-powered wearable ultrasound for maternal health monitoring in Kenya. These moves aim to reshape Medtronic's portfolio and prioritize higher-margin therapies, with potential operational risks and execution challenges.

Medtronic has started an exchange offer to split off up to 80.1% of MiniMed shares, completing a two-step separation process. Medtronic currently owns 89.9% of MiniMed, which went public in March. The offer allows exchanging Medtronic shares for MiniMed shares at a 7% discount. MiniMed's shares have risen 18% since its IPO, reaching $21.50. Medtronic aims to focus on cardiovascular, neuroscience, and surgical portfolios.

Medtronic (MDT) is offering shareholders the option to exchange their ordinary shares for shares of MiniMed, a company being separated from Medtronic. Participation is voluntary, and eligible shares must have been held for at least one year. The exchange offer expires on October 9, 2026, with specific deadlines for tendering and withdrawing shares. Medtronic and MiniMed have filed relevant documents with the SEC.